"In September 2016, an update research report was published by Baker Young on Actinogen Medical entitled: Actinogen Medical – Best Risk vs Reward Play in Alzheimer’s Dementia. This report details the investment opportunity presented by ACW, with Baker Young estimating Actinogen Medical’s target share price at $0.39, against the current share price of around $0.06."
I don't think the market has taken much note of Baker Young's research...
Ann: Appendix 4E & Financial Statements, page-3
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.5¢ |
Change
-0.001(2.78%) |
Mkt cap ! $94.93M | |||
| Open | High | Low | Value | Volume |
| 3.7¢ | 3.7¢ | 3.4¢ | $220.0K | 6.153M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 265101 | 3.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.6¢ | 175641 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| ACW (ASX) Chart |